Tag: Pfizer
Pfizer: acquisition for the takeover of ReViral
(CercleFinance.com) – Pfizer announces that it has entered into an agreement to acquire ReViral, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antiviral treatments that…
Pfizer: promising results for etrasimod
(CercleFinance.com) – Pfizer today announced positive results from a Phase 3 study of etrasimod as a potential treatment for moderate to severe active ulcerative colitis (UC). In this 52-week study,…
Pfizer: Positive CHMP opinion for KEYTRUDA
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Pfizer: Positive results of a trial around etrasimod
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Pfizer: positive results of a trial around etrasimod
(CercleFinance.com) – Pfizer today presents the first positive results of a phase 3 study on etrasimod as a treatment for severe active ulcerative colitis (UC). In the study, patients treated…
Pfizer: Profits made in Russia donated to Ukraine
Read also (CercleFinance.com) – If Pfizer announces that it stands alongside the world community to oppose the Russian war in Ukraine, the laboratory indicates that cutting off the flow of…
Pfizer: a fourth dose of vaccine against covid necessary, according to the CEO – 03/14/2022 at 13:45
(AOF) – In an interview with CBS News, Albert Bourla, CEO of Pfizer, said a fourth dose of the covid vaccine would be needed this year. He believes that the…
Pfizer: Arena acquisition complete
(CercleFinance.com) – Pfizer said on Friday that it had completed the acquisition of Arena Pharmaceuticals, a clinical-stage biotechnology company which it had initially announced the acquisition last December. Arena’s portfolio…
Pfizer: phase 2/3 study for Paxlovid in children
(CercleFinance.com) – Pfizer announces that it has launched a phase 2/3 study, EPIC-PEDS, to evaluate the safety, pharmacokinetics and efficacy of Paxlovid in non-hospitalized children with Covid-19 and symptomatic, who…
Pfizer: Positive Results from a Phase 3 Trial in CDI
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
PFIZER INC: Goldman Sachs is not inspired by the file
Goldman Sachs research confirms his advice and maintains his neutral opinion on the matter. The price target has been revised downwards to…
Pfizer predicts sales of $54 billion in 2022 for COVID vaccine and pill
The vaccine, based on the mRNA technology that is also the source of rival Moderna’s vaccines, is used in more than 160 countries, including the United States, and Pfizer aims…